Clinical decision on a patient with ALK+diffuse large B cell lymphoma
10.3969/j.issn.1000-8179.2016.09.350
- VernacularTitle:ALK+弥漫大B细胞淋巴瘤患者临床决策探讨
- Author:
Ling DONG
;
Bin MENG
;
Xinwei ZHANG
;
Xiuyu SONG
;
Ximei ZHANG
;
Qiongli ZHAI
;
Xia LIU
;
Yun HOU
;
Wei LI
;
Xianhuo WANG
;
Huaqing WANG
;
Kai FU
;
Huilai ZHANG
- Publication Type:Journal Article
- Keywords:
anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma (ALK+DLBCL);
Crizotinib;
multiple disciplinary team (MDT)
- From:
Chinese Journal of Clinical Oncology
2016;43(9):385-391
- CountryChina
- Language:Chinese
-
Abstract:
Anaplastic lymphoma kinase (ALK)-positive diffuse large B-cell lymphoma (DLBCL) is a rare and distinct variant of DLBCL. It is classified as a unique subtype of DLBCL in the 2008 WHO classification of lymphomas. No standard and effective therapeutic regi-men is available for ALK+DLBCL because it shows a more aggressive clinical course and frequent relapse. Therefore, a standardized and individualized treatment is needed to benefit more patients diagnosed with ALK+DLBCL through a multiple disciplinary team. This arti-cle presents a case of an ALK+DLBCL patient who relapsed after transplantation and was successfully treated with the ALK kinase inhibi-tor Crizotinib.
